ACHILLES THERAPEUTICS PL-ADR (ACHL)
US00449L1026 - ADR
Overall ACHL gets a fundamental rating of 3 out of 10. We evaluated ACHL against 588 industry peers in the Biotechnology industry. While ACHL has a great health rating, there are worries on its profitability. ACHL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ACHL had negative earnings in the past year.
ACHL had a negative operating cash flow in the past year.
In the past 5 years ACHL always reported negative net income.
In the past 5 years ACHL always reported negative operating cash flow.
1.2 Ratios
ACHL has a Return On Assets (-43.15%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -48.94%, ACHL is doing good in the industry, outperforming 69.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.15% | ||
| ROE | -48.94% | ||
| ROIC | N/A |
ROA(3y)-31.57%
ROA(5y)-24.64%
ROE(3y)-35.39%
ROE(5y)-27.5%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACHL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACHL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ACHL has been increased compared to 5 years ago.
There is no outstanding debt for ACHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACHL has an Altman-Z score of -1.85. This is a bad value and indicates that ACHL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ACHL (-1.85) is comparable to the rest of the industry.
ACHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.85 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ACHL has a Current Ratio of 8.57. This indicates that ACHL is financially healthy and has no problem in meeting its short term obligations.
ACHL has a Current ratio of 8.57. This is in the better half of the industry: ACHL outperforms 75.34% of its industry peers.
A Quick Ratio of 8.57 indicates that ACHL has no problem at all paying its short term obligations.
ACHL has a Quick ratio of 8.57. This is in the better half of the industry: ACHL outperforms 75.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.57 | ||
| Quick Ratio | 8.57 |
3. Growth
3.1 Past
ACHL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.40%.
EPS 1Y (TTM)4.4%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q24.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 10.51% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.67%
EPS Next 2Y15.91%
EPS Next 3Y-17.11%
EPS Next 5Y10.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACHL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACHL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ACHL's earnings are expected to decrease with -17.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.91%
EPS Next 3Y-17.11%
5. Dividend
5.1 Amount
No dividends for ACHL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACHILLES THERAPEUTICS PL-ADR
NASDAQ:ACHL (4/24/2024, 7:00:00 PM)
After market: 0.785 +0 (+0.15%)0.7838
+0 (+0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap31.26M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -43.15% | ||
| ROE | -48.94% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.57 | ||
| Quick Ratio | 8.57 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)4.4%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y37.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y